Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab SC vs IV in PNH
NCT03748823Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2019
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Serum Trough Concentration of Ravulizumab at Day 71. Started Feb 2019; status: completed.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03748823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748823.